Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 3/20 | 0.82 |
| ▸ | MC5R | P33032 | 2/20 | 0.82 |
| ▸ | MC3R | P41968 | 2/20 | 0.82 |
| ▸ | MC1R | Q01726 | 2/20 | 0.82 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.70 |
| ▸ | CTSL | P07711 | 3/20 | 0.69 |
| ▸ | CTSS | P25774 | 3/20 | 0.69 |
| ▸ | CTSK | P43235 | 3/20 | 0.69 |
| ▸ | CTSH | P09668 | 1/20 | 0.69 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.64 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.63 |
| ▸ | GLP1R | P43220 | 4/20 | 0.63 |
| ▸ | GCGR | P47871 | 3/20 | 0.60 |
| ▸ | NMBR | P28336 | 1/20 | 0.60 |
| ▸ | GRPR | P30550 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Intermedine SCHEMBL20548027 | 1.00 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29358645 | 1.00 | MC4R (0.82) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29534172 | 0.98 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29430238 | 0.96 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| SCHEMBL29533733 | 0.96 | MC4R (0.78) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29419548 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL22463810 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29352792 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL22463811 | 0.96 | MC4R (0.81) | MC4RMC5RMC3RMC1RC5AR1 | |
| Afamelanotide SCHEMBL29533175 | 0.95 | MC4R (0.80) | MC4RMC5RMC3RMC1RC5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 674 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099249-A1 | MODIFIED AND UNMODIFIED PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR USE IN SUBJECTS HAVING INCREASED AMYLOID-BETA AND/OR PHOSPHO-TAU-PROTEIN LOAD AND/OR NEUROINFLAMMATION | PAM THERAGNOSTICS GMBH (DE) | 2026-05-15 | — | — | WO | claimed |
| US-20260133154-A1 | ELECTROCHEMICAL SHOTGUN TAGGING ASSAY WITH CATALYTIC AMPLIFICATION | OXFORD UNIV INNOVATION LIMITED (GB) | 2026-05-14 | — | — | US | claimed |
| EP-3532092-B1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-29 | — | — | EP | claimed |
| US-12350488-B2 | System and method for intermittent electrical modulation | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2025-07-08 | — | — | US | claimed |
| US-12352746-B2 | Peptide-comprising electrode | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-07-08 | — | — | US | claimed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-20250059505-A1 | IMPROVED METHODS FOR INDUCING THE MATURATION OF MAMMALIAN CELLS | REVERSE BIOENGINEERING INC (US) | 2025-02-20 | — | — | US | claimed |
| US-20250026803-A1 | IMMUNOGLOBULINS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-23 | — | — | US | claimed |
| CN-118304263-B | Synergistic mild photo-thermal Wen Minzhi plastid guided by photo-acoustic imaging and application | 山东大学 | 2024-11-19 | — | — | CN | claimed |
| US-20240369548-A1 | ELECTROCHEMICAL SHOTGUN TAGGING ASSAY | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-11-07 | — | — | US | claimed |
| WO-2023283386-A2 | SAFER PSYCHOACTIVE COMPOSITIONS | ARCADIA MEDICINE, INC. (US) | 2023-01-12 | — | — | WO | claimed |
| EP-4110372-A1 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| EP-4111201-A1 | METHODS FOR DETERMINING PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) AND ITS USE FOR DIAGNOSTIC PURPOSE | PAM Theragnostics GmbH (DE) | 2023-01-04 | — | — | EP | claimed |
| WO-2022256720-A2 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE | ARCADIA MEDICINE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| EP-4097458-A1 | ANALYTE DETECTION WITH REDOX ACTIVE POLYMER-COATED ELECTRODE | Oxford University Innovation Limited (GB) | 2022-12-07 | — | — | EP | claimed |
| CN-115227876-A | Preparation method of tissue engineering epidermis | 福建省海西细胞生物工程有限公司 | 2022-10-25 | — | — | CN | claimed |
| CN-115181719-A | Serum-free medium for culturing tissue engineering epidermis | 福建省海西细胞生物工程有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-115066254-A | Human anti-inflammatory peptides for inhalation treatment of inflammatory lung diseases | 阿德维塔生命科学有限责任公司 | 2022-09-16 | — | — | CN | claimed |
| US-11401315-B2 | Immunoglobulins and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-02 | — | — | US | claimed |
| CN-114317612-A | RNA preparations comprising purified modified RNA for reprogramming cells | 宾夕法尼亚州大学信托人 | 2022-04-12 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260133154-A1 | ELECTROCHEMICAL SHOTGUN TAGGING ASSAY WITH CATALYTIC AMPLIFICATION | BTD, APEX1, ACP1 | MC4R 2441/4885MC5R 1670/4885MC3R 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.